Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This month tags : Pharm-country save search
Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024
Published: 2024-04-18 (Crawled : 00:00) - biospace.com/
QSI | $1.5 -0.66% 320K
|
Professional, Scientific, and T...
|
| O: -0.65%
H: 0.0%
C: 0.0%
first report financial results
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
RLYB | $1.72 2.99% 210K
|
|
| O: -4.44%
H: 0.0%
C: 0.0%
pharmacy review care meeting
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
URGN | $14.03 -1.61% 170K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
association for meeting benefits
Lipella Pharmaceuticals Expands its Advisory Board
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
LIPO | $0.718 0.66% 2.3K
|
|
| O: -0.96%
H: 5.56%
C: 4.17%
pharmaceuticals
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
KRMD | $2.07 0.49% 30K
|
Health Technology
|
| O: -0.94%
H: 4.29%
C: 0.95%
first report medical financial results
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.4 0.75% 300K
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $14.03 -1.61% 170K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.615 0.55% 550K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
|
| O: 1.17%
H: 0.29%
C: -5.41%
htx-100 pharmaceuticals
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
IOBT | $1.47 45K
|
|
| O: 0.65%
H: 1.92%
C: -3.21%
biotech commercialization
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
SNGX | $0.406 -6.73% 800K
|
Health Technology
|
| O: 75.34%
H: 37.73%
C: -30.58%
fda drug marburg infection designation for grants
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
LEGN | $46.36 -1.61% 510K
|
Health Technology
|
| O: 0.02%
H: 0.22%
C: -0.88%
first conference biotech results
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PTCT | $25.02 1.34% 410K
|
Health Technology
|
| O: 2.01%
H: 1.35%
C: -0.18%
first conference therapeutics financial results
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.91 2.05% 22M
|
Health Technology
|
| O: 0.11%
H: 0.38%
C: -0.04%
meeting
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
SNGX | $0.406 -6.73% 800K
|
Health Technology
|
| O: 3.67%
H: 0.46%
C: -19.02%
fda drug infection designation for grants
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | News | $66.33 0.26% 2.8M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.75 -6.89% 1.2M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.99 4.18% 25K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | $1.72 2.99% 210K
|
|
| O: -3.03%
H: 4.38%
C: 1.87%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
risk solutions for collaboration
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
TRVI | $2.7 0.56% 55K
|
Health Technology
|
| O: 2.77%
H: 1.59%
C: -8.57%
conference presentation international therapeutics
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.91 2.05% 22M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.